Fabentech’s diverse portfolio features life-saving solutions designed to neutralise the most critical viruses and biological toxins, providing a crucial defence against potentially deadly threats.
The resurgence of bioterrorism plots involving the use of biological toxins highlights the importance of protecting ourselves against potential attacks. In this context, we are building a therapeutic arsenal of specific and effective medical countermeasures.
Biodefence antidote #1
Fabentech has initiated, in collaboration with Ministry of Defence and the DGA [General Directorate of Armaments], a partnership aiming to develop, produce and market an antidote to combat a plant-based toxin categorised as a top-priority biothreat with neither vaccines nor treatments available at this stage.
Biodefence antidote #2
Proof of concept
Fabentech is leading a proof-of-concept study targeting a new identified plant-based toxin. This program is supported by the European Defence Fund through the European COUNTERACT project, coordinated by CEA. It is aiming to increase EU preparedness for immediate response to Chemical-Biological Radiological and Nuclear (CBRN) threats.
Emerging infectious diseases
Fabentech has over 14 years of expertise in the Research and Development of immunotherapies against emerging infectious diseases.
Since 2009, Fabentech has been involved in programmes intended to combat H5N1 avian influenza, the Ebola haemorrhagic fever and the Crimean-Congo hemorrhagic fever (CCHF). Fabentech has notably developed a product against the H5N1 avian influenza (FabenFLU®) and a product against Ebola under the aegis of the World Health Organisation (WHO) and with the support of the European Medicines Agency (EMA).
EID treatment #1 FabenFLU®
Treating post-exposure H5N1 avian influenza infection
H5N1 avian influenza causes a highly infectious, severe respiratory disease in humans, with a mortality rate reaching 60%¹. The virus primarily spreads from birds to humans with few cases of human-to-human transmission. There are currently no treatments available. If the virus were to mutate and become easily transmissible among humans, it could lead to a global pandemic.
FabenFLU® is fully validated anti-H5N1 antidote and obtained an Orphan Drug Designation status in the EU.
EID treatment #2 FabenCOV®
Treatment against Sars-Cov-2 infections
Covid-19 infection is a respiratory illness caused by the SARS-CoV-2 virus, which can lead to a range of symptoms from mild to severe, and has resulted in a global pandemic². FabenCOV® treatment is designed to treat infected adults at risk with comorbidities.
This project has received funding from both BPI France and the European Union’s Horizon Europe research and innovation programme.
EID treatment #3 NIPAH
Proof of concept
Treatment against Nipah infections
Nipah virus is an infectious agent causing a severe respiratory and neurological disease with fatality rate ranging from 40 to 75% with neither vaccines nor treatments available³. Nipah infection is a zoonotic viral disease with evidence of human-to-human transmissions primarily through close contact and possibly through airborne transmission.
This project aims to develop treatment of post-exposure Nipah infection and is funded through France 2030 Emerging Infectious Diseases programme.